Fourteen days after being injected with an AstraZeneca “vaccine” a 25-year-old woman suffered a transplant rejection. Almost four and a half years earlier she had a successful kidney transplant and she did not report any difficulties until after “vaccination.”
A case report published in Nature on 2 March 2022 details this patient’s transplant rejection:
In this paper, we present a newly developed acute humoral and cellular rejection with acute allograft [transplant] failure and need of haemodialysis 14 days after administration of the adenovirus vectored SARS-CoV-2 vaccine (AstraZeneca; CHADOx1, AZD1222). This occurred in a patient who previously had an asymptomatic Covid-19 infection. Case reports of acute allograft rejection after vaccination against SARS-CoV-2 can help stratify risk groups of patients who develop hyperimmune reactions.
Individuals who have undergone kidney transplants have been identified as high-risk populations and prioritised for vaccination, but have been excluded from major severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine clinical trials.
There has been a rapid vaccine development in response to the pandemic, in particular with the mRNA vaccines (Pfizer-BioNTech, Moderna) and viral vector-based vaccines (Sputnik V, AstraZeneca/Oxford, Janssen/Ad26.COV.2). Despite the theoretical concerns with replication-deficient viral vector-based vaccines, immunosuppression is not considered as a contraindication to their use.
Kidney Transplant Rejection After Oxford-AstraZeneca Injection
In November 2016 the 25-year-old woman underwent successful primary deceased donor kidney transplantation (“KT”).
The case report noted that in December 2019 she was diagnosed, by the use of an RT-PCR test, with an asymptomatic Covid infection. There is a “Covid Lie” central to the Covid deceit in this statement – a PCR test is not able to diagnose or identify infections.
On 11 April 2021, she was “vaccinated” with the AstraZeneca’s Covid injection. Fourteen days later she was admitted to the intensive care unit. She complained of fatigue, general weakness, and vomiting, with the inability to eat or drink. When tested she showed signs of renal or kidney function decline.
Although tests later showed her kidney function began to improve, the function was still abnormal. So, she was referred to the transplantation centre. There, tests showed she had developed antibodies to both the SARS-CoV-2 spike protein and N-protein.
For ease of understanding of the excerpts from the case report shown below, here are some explanations of the words and acronyms used:
Allograft is the transplant of an organ or tissue from one individual to another of the same species.
Antigens are weakened or inactive parts of a particular organism that triggers an immune response within the body.
Adjuvants are vaccine components that enhance the magnitude, breadth and durability of the immune response.
Transverse Myelitis is a disorder caused by inflammation of the spinal cord.
Anti-HLA is an acronym for anti-human leukocyte antigen. Anti-HLA antibodies are formed by the immune system when you are exposed to proteins that appear similar to tissue types. This most commonly occurs in the setting of previous transplantation, pregnancy, or blood transfusion. Occasionally the cause of anti-HLA antibody formation is not known. Unfortunately, once you have anti-HLA antibodies, they do not go away on their own.
KTR is an acronym for kidney transplant recipients.
Hyperimmune response is a response by an overactive immune system. Common overactive immune system responses are asthma, eczema and allergic rhinitis. In some people, an overactive immune response can trigger a cytokine storm.
The case report stated:
Vaccine antigen or adjuvants can induce a generalised systemic inflammation response or could promote allograft-directed immune responses. Adenovirus vectors can trigger a potent immune response through complement activation and induce a diverse cytokine response. Three cases of transverse myelitis were reported after ChAdOx1 NCoV-19 (AZD1222) booster vaccination. They were described as potentially related to the vaccination, later they were considered as idiopathic spinal cord demyelination or pre-existing multiple sclerosis. The relationship between the vaccine and acute transverse myelitis remained possible in only one of the cases.
Concerns arose from the observation of high incidence of anti-HLA (only a small fraction was donor-specific antibodies) antibodies in KTR who received influenza A(H1Na1) pdm09 vaccine in 2009, which contained the squalene-based AS03 adjuvant system. Several recombinant spike protein SARS-CoV-2 vaccines contain adjuvant (AS03, the novel Matrix M1 adjuvant), such as Novavax/NVX-CoV2373. However, the viral-vectored and mRNA vaccines do not generally contain adjuvants. One case report of acute cellular kidney rejection was reported after the second dose of mRNA vaccine (BNT162b2, Pfizer-BioNTech) to date. [see below]
The acute humoral and cellular rejection presented in the case report can be explained as a hyperimmune response to the first dose of a viral vector vaccine. This is represented by high levels of antibodies against the spike protein SARS-CoV-2 in a patient with autoimmune disease and previous asymptomatic Covid-19 infection.